Wall Street Zen Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Sell

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other equities analysts also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 1st. Wells Fargo & Company initiated coverage on shares of Milestone Pharmaceuticals in a report on Thursday, September 11th. They set an “overweight” rating and a $4.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.50.

Milestone Pharmaceuticals Trading Down 18.3%

Milestone Pharmaceuticals stock opened at $2.41 on Friday. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $3.06. The company’s fifty day moving average price is $2.18 and its two-hundred day moving average price is $1.91. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. The company has a market capitalization of $205.26 million, a price-to-earnings ratio of -2.94 and a beta of 0.40.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. On average, analysts forecast that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several large investors have recently bought and sold shares of MIST. Sapient Capital LLC bought a new stake in Milestone Pharmaceuticals in the 3rd quarter valued at $25,000. Bay Rivers Group acquired a new position in shares of Milestone Pharmaceuticals during the second quarter valued at about $28,000. Bank of America Corp DE lifted its stake in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after buying an additional 16,044 shares during the period. Stephenson & Company Inc. bought a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at about $40,000. Finally, Creative Planning grew its position in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares in the last quarter. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.